Seeking Alpha
16 Nov 2026, 08:22 UTC · 17h ago
Iovance: The Lung Selloff Went Too Far For A Business Growing 77%
Impact · against what's priced in
IOVA is largely a trade on whether the lung cancer trial disappointment was an overreaction. While Amtagvi revenue growth is strong, the market has already priced in the failure of the lung cancer response rate (8.51%) to beat the benchmark.
- IOVA+0.10
No priced-in read yet
- In context
Strong Amtagvi revenue growth (77%) and reduced cash burn (-$4.47M) provide a valuation floor, but the negative catalyst of the lung cancer data (8.51% response rate) has already triggered a 47.6% selloff.
Read from the article alone

Top 1 mover · tap to explore




